In today’s session EXACT Sciences Corporation (EXAS) recorded an unusually high (133) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the December, 2016 put, expecting serious EXAS decrease. With 133 contracts traded and 6564 open interest for the Dec, 16 contract, it seems this is a quite bearish bet. The option with symbol: EXAS161216P00016000 closed last at: $2.1 or 180% up. About 668,786 shares traded hands. EXACT Sciences Corporation (NASDAQ:EXAS) has risen 87.44% since April 18, 2016 and is uptrending. It has outperformed by 83.01% the S&P500.
EXACT Sciences Corporation (NASDAQ:EXAS) Ratings Coverage
Out of 13 analysts covering EXACT Sciences (NASDAQ:EXAS), 5 rate it a “Buy”, 1 “Sell”, while 7 “Hold”. This means 38% are positive. EXACT Sciences has been the topic of 27 analyst reports since July 24, 2015 according to StockzIntelligence Inc. The rating was maintained by TH Capital on Friday, October 30 with “Buy”. The firm has “Neutral” rating given on Tuesday, October 6 by Goldman Sachs. Jefferies maintained the shares of EXAS in a report on Thursday, February 25 with “Buy” rating. On Tuesday, November 1 the stock rating was maintained by Lake Street with “Hold”. BTIG Research initiated EXACT Sciences Corporation (NASDAQ:EXAS) on Friday, December 18 with “Buy” rating. The firm earned “Hold” rating on Wednesday, October 26 by Benchmark. As per Thursday, October 1, the company rating was initiated by Craig Hallum. The rating was maintained by Wedbush with “Neutral” on Thursday, October 8. The stock has “Hold” rating given by Lake Street on Wednesday, October 7. The rating was maintained by Goldman Sachs on Monday, August 15 with “Neutral”.
According to Zacks Investment Research, “EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated.”
Insitutional Activity: The institutional sentiment increased to 1.48 in 2016 Q2. Its up 0.06, from 1.42 in 2016Q1. The ratio increased, as 18 funds sold all EXACT Sciences Corporation shares owned while 41 reduced positions. 30 funds bought stakes while 54 increased positions. They now own 87.89 million shares or 11.45% more from 78.86 million shares in 2016Q1.
Stonebridge Capital has 0.08% invested in the company for 13,745 shares. Legal General Grp Inc Public Limited Company accumulated 0% or 21,166 shares. The Ohio-based Strs Ohio has invested 0.04% in EXACT Sciences Corporation (NASDAQ:EXAS). Fmr Ltd Llc has 0% invested in the company for 2.38M shares. Rhumbline Advisers last reported 0% of its portfolio in the stock. The Colorado-based Pub Employees Retirement Association Of Colorado has invested 0% in EXACT Sciences Corporation (NASDAQ:EXAS). Parametric accumulated 0% or 46,840 shares. Ladenburg Thalmann Serv Incorporated accumulated 5,586 shares or 0% of the stock. Lpl Ltd last reported 25,306 shares in the company. Susquehanna International Group Ltd Liability Partnership owns 135,387 shares or 0% of their US portfolio. Teton Advsrs reported 268,551 shares or 0.3% of all its holdings. Point72 Asset Mgmt Ltd Partnership holds 507,175 shares or 0.04% of its portfolio. Moreover, Kcg Incorporated has 0.02% invested in EXACT Sciences Corporation (NASDAQ:EXAS) for 84,152 shares. Blackrock Japan Limited has 0% invested in the company for 97,661 shares. Moreover, Amalgamated Retail Bank has 0.01% invested in EXACT Sciences Corporation (NASDAQ:EXAS) for 10,229 shares.
Insider Transactions: Since July 25, 2016, the stock had 2 insider buys, and 6 sales for $25.84 million net activity. The insider Conroy Kevin T sold $10.48M. Another trade for 3,380 shares valued at $60,613 was bought by Zanotti Katherine S. Sterling Lionel had bought 5,000 shares worth $90,500. 7,383 shares with value of $109,416 were sold by LIDGARD GRAHAM PETER on Monday, July 25. COWARD D SCOTT sold 1,701 shares worth $30,584. Another trade for 7,359 shares valued at $109,060 was made by ARORA MANEESH on Monday, July 25.
Exact Sciences Corporation is a molecular diagnostics firm focused on the early detection and prevention of some forms of cancer. The company has a market cap of $1.55 billion. The Company’s product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline. It currently has negative earnings. It has developed a non invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer.
EXAS Company Profile
Exact Sciences Corporation, incorporated on February 10, 1995, is a molecular diagnostics firm focused on the early detection and prevention of some forms of cancer. The Company’s product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline. The Firm has developed a non invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. The Company’s Cologuard test is a non invasive stool based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody based fecal immunochemical test (FIT). The United States Food and Drug Administration (FDA) approved Cologuard for use as sDNA non-invasive colorectal cancer screening test. Cologuard is available through healthcare providers.
More important recent EXACT Sciences Corporation (NASDAQ:EXAS) news were published by: Fool.com which released: “1 Sentence in Exact Sciences Corporation’s Q3 Report Cost It 16% in October” on November 07, 2016, also Fool.com published article titled: “Here’s Why Exact Sciences Corporation’s Stock Is Dropping Today”, Fool.com published: “Exact Sciences Corp. Gets a Better Balance Sheet” on November 03, 2016. More interesting news about EXACT Sciences Corporation (NASDAQ:EXAS) was released by: Prnewswire.com and their article: “Exact Sciences Appoints Jeff Elliott Chief Financial Officer” with publication date: November 08, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.